464213-10-3CN=C(NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1AXJQVVLKUYCICH-OAQYLSRUSA-NIbipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
使用(S)-SLV 319 is a potent, selective CB1 receptor antagonist.
現在のフィルター条件では反応記録がありません。
読み込み中…
464213-10-3DTXSID70963572CHEMBL412262